Cis-Diamminedichloroplatinum Ii
Lip And Oral Cavity Carcinoma
Explore 9 assets in Lip And Oral Cavity Carcinoma →Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Loren Mell, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03383094CT.gov Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | — | Active Not Recruiting | — | — | — |
NCT00006106CT.gov ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lip And Oral Cavity Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cis-Diamminedichloroplatinum Ii (this asset) | Loren Mell, MD | P2 | B · 60 |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Pembrolizumab | Loren Mell, MD | P2 | CCC |
| (18F)FPPRGD2 | Sanjiv Sam Gambhir | P1/2 | CCC |
| Fludeoxyglucose | Sanjiv Sam Gambhir | P1/2 | CCC |
| Anti-Her2 Antibody-Drug Conjugate A166 | Klus Pharma Inc. | P1/2 | CCC |
| Talaporfin | Light Sciences LLC | P1 | CC |
| Mogamulizumab | Osaka University | P1 | CC |
| Brodalumab | Brian Henick, MD | P1 | CC |
+13 more in the Lip And Oral Cavity Carcinoma cohort
Other indications for Cis-Diamminedichloroplatinum Ii
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Squamous Cell Lung Carcinoma | — | P4 | BBB · 78 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 77 |
| Adenocarcinoma | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cis-Diamminedichloroplatinum Ii in Lip And Oral Cavity Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cis-diamminedichloroplatinum-ii-lip-and-oral-cavity-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →